We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Charu Aggarwal, MD, MPH
Alexander Drilon, MD
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Early Recognition and Diagnosis of Castleman Disease
Sanam Loghavi, MD
Razelle Kurzrock, MD, FACP
Keeping Pace in Lung Cancer - Breaking Barriers: Advances in Treating EGFR Exon 20 Insertions in NSCLC
Heather Wakelee, MD, FASCO
Lyudmila Bazhenova, MD
MET Inhibition in Metastatic NSCLC “In the Spotlight”
Paul Paik, MD
D. Ross Camidge, MD, PhD
Keith Kerr, BSc, MB ChB
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Mamta Parikh, MD, MS
Daniel P. Petrylak, MD
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Robert L. Coleman, MD, FACOG, FACS
Susana Campos, MD, MPH
Domenica Lorusso, MD, PhD
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Benjamin Levy, MD
Rebecca Heist, MD, MPH
Peter Bela Illei, MD
TROP2-Directed ADCs in Lung Cancer
Justin Gainor, MD
TROP2-Directed ADCs in Breast Cancer
Sara A. Hurvitz, MD, FACP
TROP2-Directed ADCs in Bladder Cancer
Gopa Iyer, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education